

## **Cooperation on Target Validation established between GANYMED Pharmaceuticals AG and the University of Ghent**

Mainz and Ghent, June 5th, 2003

GANYMED Pharmaceuticals AG and the University of Ghent established a cooperation on the immunohistochemical validation of GANYMED's tumorselective, membrane bound „ideal“ targets in oncology.

„The Department of Pathology of the University Hospital Ghent (Director Professor Dr. M. Praet) has high expertise in immunohistochemistry with novel target-specific antibodies and is assisting GANYMED in validation of our targets in human tumour tissue to establish them for antibody treatment of cancer“ Dr. Özlem Türeci, CSO of GANYMED, underlined the importance of the cooperation.

„We are looking forward to this cooperation and are enthusiastic to be involved in the validation of this promising targets“, Dr. Karl Dhaene, project leader at the Department in Ghent, emphasizes the interest of his research group.

GANYMED Pharmaceuticals AG is an independent biotechnology company and was founded 2001 by a renowned international team of scientists and oncologists of the Johannes-Gutenberg-University Mainz and the University and ETH Zurich. The company is based in Mainz, Germany. GANYMED's mission is to develop tailored medical solutions for cancer and infectious disease based on highly selective disease specific antigens as targets for molecular and immunological therapeutics and diagnostics. GANYMED's integrated technology platforms allow the systematic search and comprehensive identification of antigens not only for cancer but also for even hitherto unknown pathogens providing new avenues to address major diseases like multiple sclerosis, juvenile diabetes mellitus, Crohn Disease and others. GANYMED's vision is to become a favoured partner for the pharmaceutical industry as a source for high quality, „ideal“ targets and new drugs.

The Institute of Pathology of the University of Ghent (Director: Prof. Dr. M. Praet) is named after Prof. Dr. N. Goormaghtigh who, in the first half of the past century, discovered a special human kidney cell type involved in blood-pressure regulation. Nowadays, the Institute is fully equipped for diagnostic and scientific tissue examination and analysis. Aside immunohistochemistry, great expertise is available for the detection of diseased genetic material in recent as well as in archived tissue samples. The archive goes back to as far as 1963. The Institute has a multidisciplinary interest and is vividly collaborating with the Departments of Medical Genetics and Clinical Chemistry. Further, the subdivision of Molecular Pathology is actively participating in national programs to establish and validate diagnostic molecular assays. Among many others, special interest goes to the study of non-tumoral and tumoral lung diseases as well as to asbestos-induced mesothelioma. Therefore, the Institute is in close contact with pulmonologists active in european studies for research and treatment of the aforementioned diseases.

For further inquiries / contact:

**GANYMED Pharmaceuticals AG**

Mrs. Anja Gruschwitz  
Freiligrathstrasse 12  
D-55131 Mainz  
Germany

phone: (+49) 6131 / 1440 109

fax: (+49) 6131 / 1440 111

[info@ganymed-pharmaceuticals.com](mailto:info@ganymed-pharmaceuticals.com)

**Institute of Pathology  
University Hospital Ghent**

Dr. Karl Dhaene  
De Pintelaan 185, Building A  
B-9000 Ghent  
Belgium

phone: (+32) 92403665

fax: (+32) 92404965

[karl.dhaene@ugent.be](mailto:karl.dhaene@ugent.be)